Frazier Life Sciences Amends Phathom Pharma Stake

TL;DR

Frazier Life Sciences just updated their stake in Phathom Pharma. Big move.

AI Summary

Frazier Life Sciences Public Fund, L.P. has amended its Schedule 13D filing regarding Phathom Pharmaceuticals, Inc. as of August 22, 2024. The filing indicates a change in beneficial ownership, with Frazier Life Sciences Public Fund, L.P. now holding a significant stake in Phathom Pharmaceuticals. Specific details on the exact percentage or number of shares are not provided in this excerpt, but the amendment signifies a notable event for the company.

Why It Matters

This amendment signals a potential shift in the ownership structure or investment strategy of Phathom Pharmaceuticals, which could impact its stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position, which can lead to increased volatility.

Key Players & Entities

• Frazier Life Sciences Public Fund, L.P. (company) — Filer of the Schedule 13D/A amendment
• Phathom Pharmaceuticals, Inc. (company) — Subject company of the filing
• ALBERT CHA (person) — Group member of the filer
• DANIEL ESTES (person) — Group member of the filer
• PATRICK J. HERON (person) — Group member of the filer
• JAMES N. TOPPER (person) — Group member of the filer

FAQ

Filing Documents

• d879736dsc13da.htm (SC 13D/A) — 373KB
• 0001193125-24-205352.txt ( ) — 376KB

From the Filing

SC 13D/A 1 d879736dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D U NDER THE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. 8)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 20, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 71722W107 1. Name of Reporting Persons. Frazier Life Sciences IX, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 5,827,415 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 5,827,415 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,827,415 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 8.5 % (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 5,827,415 shares of Common Stock held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences IX, L.P. (2) Based on (i) 59,593,971 shares of Common Stock outstanding on August 6, 2024, as set forth in the Issuers Form 10-Q filed with the SEC on August 8, 2024, and (ii) 8,695,652 shares of Common Stock that were sold by the Issuer on August 20, 2024 as described in the Issuers Current Report on Form 8-K filed with the SEC on August 19, 2024. Page 2 CUSIP No. 71722W107 1. Name of Reporting Persons. FHMLS IX, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 5,827,415 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 5,827,415 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,827,415 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 8.5 % (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 5,827,415 shares of Common Stock held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences IX, L.P. (2) Based on (i) 59,593,971 shares of Common Stock outstanding on August 6, 2024, as set forth in the Issuers Form 10-Q filed with the SEC on August 8, 2024, and (ii) 8,695,652 shares of Common Stock that were sold by the Issuer on August 20, 2024 as described in the Issuers Current Report on Form 8-K filed

View Full Filing

View this SC 13D/A filing on SEC EDGAR